تخطَّ إلى المحتوى
دليل الأدوية المصري
تابع آخر تحديثات الأسعار على واتساب

سعر ريفاكساريلت 20مجم 30 قرص 2022

Rivaxarelt 20 mg

معلومات الدواء

التفاصيل الكاملة
دواعي الاستعمالUses
  • Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillationالفئة: AdultsDailyMed (U.S. National Library of Medicine)
  • Treatment of deep vein thrombosis and pulmonary embolism (continuation after day 21)الفئة: AdultsDailyMed (U.S. National Library of Medicine)
  • Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillationPopulation: AdultsDailyMed (U.S. National Library of Medicine)
  • Treatment of deep vein thrombosis and pulmonary embolism (continuation after day 21)Population: AdultsDailyMed (U.S. National Library of Medicine)
الآثار الجانبيةSide effects
  • The most common adverse reactions are bleeding complications.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
  • Active pathological bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.نشرة دولية لنفس التركيبة · European Medicines Agency
  • Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency
تحذيرات واحتياطاتWarnings & precautions
  • Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
عرض الكل (4)
  • Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Show all (4)
التداخلات الدوائيةDrug interactions
  • Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
  • Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
  • Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
  • Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
  • Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
  • Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
  • Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
  • Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.نشرة دولية لنفس التركيبة · European Medicines Agency
  • Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
عرض الكل (4)
  • Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
  • Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
  • Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)
Show all (4)

المثائل (5)

كل المثائل والبدائل

نفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.

مثائل ريفاكساريلت 20مجم 30 قرص بنفس المادة الفعالة والتركيز، مرتبة من الأرخص
اندوريفابان 20 مجم 20 قرصAndorivaban 20 mg 20 film-coated tabletsAl Andalous Pharmaceutical Industries · أقراص مغلفة · 20 mgالأرخصالسعر260ج.م13ج.م للوحدةالفرق عن الأصليأرخص 130ج.م (33.3%)
ريفافلوفاRivaflowva 20mgGypto Pharma · 20 mgالسعر260ج.م13ج.م للوحدةالفرق عن الأصليأرخص 130ج.م (33.3%)
ريفاروسبير 20مجم 28 قرصRivarospire 20 mgInspire Pharmaceutical Company · 20 mgالسعر364ج.م13ج.م للوحدةالفرق عن الأصليأرخص 26ج.م (6.7%)
ريباتوكسابان 20مجم 30 قرصRepatoxaban 20 mg 30 tabsEva Pharma · 20 mgالسعر375ج.م12.5ج.م للوحدةالفرق عن الأصليأرخص 15ج.م (3.8%)
اورجوروكسبان 20مجم 30 قرصOrgoroxabanOrganopharma · أقراص مغلفة · 20 mgالسعر513ج.م17.1ج.م للوحدةالفرق عن الأصليأغلى 123ج.م (31.5%)

أدوية ذات صلة

نفس المادة الفعالة بتركيز آخر

منتجات أخرى من Penta Pharma-Egypt

من فئة مضاد للتجلط

المصادر

تعليقات

لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.

أضف تعليقًا

0/60

لا يُنشر أبدًا؛ للتواصل فقط إن لزم.

0/1000

من 20 إلى 1000 حرف. بدون روابط.

التعليقات للمعلومات العامة ولا تُعد نصيحة طبية. لا تذكر بيانات شخصية.